Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

NCT05280509 is registered in ClinicalTrials.gov with Telios Pharma, Inc. as lead sponsor.

NCT NCT05280509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05280509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Lead sponsor
Telios Pharma, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 9, 2022
Completion date
April 30, 2027
Enrollment
70 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, post-et myelofibrosis, post-pv mf, primary myelofibrosis